The Comprehensive Brain Tumor Program at The Mount Sinai Hospital
Mount Sinai’s Comprehensive Brain Tumor Program provides the full spectrum of care to patients with a variety of primary and secondary brain tumors, including glioblastomas, low-grade gliomas, and metastatic brain tumors.
The Comprehensive Brian Tumor Program aims to improve the quality of life for brain tumor patients through personal care plans. Our director Isabelle Germano, MD, FACS, brings more than 20 years of experience to Mount Sinai and can provide an array of novel treatment options using state-of-the-art technology.
Advanced Neurosurgical Treatments for Brain Tumors
Using advanced diagnostic tools, our multidisciplinary team of neurologists, oncologists, radiation oncologists, and neurosurgeons work together to recommend individualized treatment plans, which may include one or a combination of the following:
- Biopsy: Removal of sample cell tissues for examination
- Chemotherapy: Medications used to kill cancer cells
- Craniotomy: Surgical removal of a portion of the skull to resect brain tumors
- Radiation therapy: High-energy beams used to destroy cancer cells
We have also pioneered and mastered complex technologies to treat these tumors aggressively. Intraoperative monitoring, including brain mapping, is a technique our neurosurgeons use to identify vital areas of the brain and avoid them during surgery for safe tumor removal.
Our surgeons also performed routine brain monitoring during surgical procedures as an extra layer of safety to protect neurological function.
Access to Comprehensive Services for Brain Tumor Patients
In addition to the top neurosurgeons in the country, our patients have access to vast resources at Mount Sinai, including physical and occupational therapy, social workers, and support groups.
Mount Sinai provides palliative care and a specialized neuro-intensive care unit should those options need to be explored at any point during treatment. Our goal is to improve quality of life for patients and to prolong their length of survival.
Patients also have access to new therapies through ongoing clinical trials, one of which is called the Novocure clinical trial. Backed by the National Institutes of Health (NIH), it will assess the safety and efficacy of the NovoTTF-100A, a non-invasive therapy, for the treatment of patients with a newly diagnosed glioblastoma. Mount Sinai is one of two hospitals in New York to offer access to this innovative clinical trial. Patients will also be aware of other chemotherapy trials if they are deemed eligible by their neurosurgeon.
Comprehensive Brain Tumor Program
5 East 98th Street, 7th Floor
New York, NY 10029
To speak with someone about open brain tumor clinical trials, please contact John Percival Pena, NP, at 212-241-6252.